Arjuna Therapeutics Overview
- Status
-
Private
- Employees
-
10

- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$1.47M
- Investors
-
5
Arjuna Therapeutics General Information
Description
Developer of a novel class of orally available small molecules intended to address untreatable cancers. The company's nanomaterials aim to redefine the treatment landscape for solid tumors on both sides of the blood-brain barrier by targeting all cancers that generate high levels of Reactive Oxygen Species, enabling healthcare providers to treat cancer patients with novel drugs.
Contact Information
Website
www.arjunatherapeutics.comCorporate Office
- C-Da Xesta 78-a2
- Ligonoindustrial Novo Milla (Ames)
- 15895 A Coruna
- Spain
Corporate Office
- C-Da Xesta 78-a2
- Ligonoindustrial Novo Milla (Ames)
- 15895 A Coruna
- Spain
Arjuna Therapeutics Timeline
Arjuna Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
8. Equity Crowdfunding | 17-Oct-2022 | $1.47M | Completed | Pre-Clinical Trials | ||
7. Later Stage VC | 14-Feb-2022 | Completed | Pre-Clinical Trials | |||
6. Later Stage VC | 20-Dec-2019 | Completed | Pre-Clinical Trials | |||
5. Later Stage VC | 11-Jan-2019 | Completed | Pre-Clinical Trials | |||
4. Grant | 20-Jan-2016 | Completed | Pre-Clinical Trials | |||
3. Later Stage VC | 23-Sep-2014 | Completed | Pre-Clinical Trials | |||
2. Later Stage VC | 16-Mar-2012 | Completed | Pre-Clinical Trials | |||
1. Grant | 01-Jan-2011 | Completed | Startup |
Arjuna Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | ||||||||
Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Arjuna Therapeutics Signals
Arjuna Therapeutics Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Repsol Corporate Venturing | Corporate Venture Capital | Minority | ||
Horizon 2020 | Government | |||
Caixa Capital Risc | Venture Capital | Minority | ||
Unirisco | Venture Capital | Minority | ||
European Commission | Government |
Arjuna Therapeutics FAQs
-
Where is Arjuna Therapeutics headquartered?
Arjuna Therapeutics is headquartered in A Coruna, Spain.
-
What is the size of Arjuna Therapeutics?
Arjuna Therapeutics has 10 total employees.
-
What industry is Arjuna Therapeutics in?
Arjuna Therapeutics’s primary industry is Drug Discovery.
-
Is Arjuna Therapeutics a private or public company?
Arjuna Therapeutics is a Private company.
-
What is the current valuation of Arjuna Therapeutics?
The current valuation of Arjuna Therapeutics is
. -
What is Arjuna Therapeutics’s current revenue?
The current revenue for Arjuna Therapeutics is
. -
How much funding has Arjuna Therapeutics raised over time?
Arjuna Therapeutics has raised $8.61M.
-
Who are Arjuna Therapeutics’s investors?
Repsol Corporate Venturing, Horizon 2020, Caixa Capital Risc, Unirisco, and European Commission have invested in Arjuna Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »